Concurrent chemoradiotherapy with low dose weekly gemcitabine in stage III non-small cell lung cancer.

Abacioglu U. , Yumuk P., Caglar H., Sengoz M. , Turhal N.

BMC cancer, vol.5, pp.71, 2005 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 5
  • Publication Date: 2005
  • Doi Number: 10.1186/1471-2407-5-71
  • Title of Journal : BMC cancer
  • Page Numbers: pp.71

Abstract

Background: Combined chemoradiotherapy (CRT) is the treatment of choice for stage III NSCLC. Gemcitabine (G) is a novel deoxycitidine analogue that has been proven to be a potent radiosensitizer. Twenty-two consecutive patients were treated with concurrent CRT to demonstrate the tolerability and efficacy of low dose G given weekly as radiosensitizer in stage III NSCLC.